Account
Articles
24.04.2020
What are Managed Entry Agreements

Arrangements made between manufacturers and payers which are being implemented for innovative treatm...

Read more
Articles
27.03.2020
NICE postpones technology appraisals

NICE confirmed that they will be prioritising work that is therapeutically critical or relates to ad...

Read more
Articles
13.02.2020
Westminster Health Forum

The Westminster Health Forum organise senior level conferences on public policy relating to health a...

Read more
Articles
30.01.2020
NICE EMA scientific advice

With the UKs withdrawal from the European Union, NICE’s relationship with EMA and indeed, the para...

Read more
Articles
13.11.2019
Medical device market access

What are the pro’s and cons of seeking NICE approval using the Medical Technologies Evaluation Pro...

Read more
Publications
06.11.2019
A comparison of oncology and non-oncology appraisa

In this study, we compared the use of financial agreements for oncology and non-oncology drugs asses...

Read more
Articles
13.09.2019
Evidence base for Yescarta and Kymriah

Is the evidence base for high-cost CAR T-cell therapies Kymriah and Yescarta sufficient to be grante...

Read more
Articles
04.09.2019
Are access agreements essential for NICE access

This study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...

Read more
Articles
13.08.2019
Is market access for oncology treatments easier in

This study from 2017 - 2019 compares the outcomes for oncology and non-oncology appraisals conducted...

Read more
Articles
31.07.2019
Commercial patient access scheme

In England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.